Testing effectiveness (Phase 2)Ended earlyNCT04538378
What this trial is testing
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Who this might be right for
EGFR-Mutated Non-Small-Cell Lung CarcinomaSmall Cell/Neuroendocrine
National Cancer Institute (NCI) 4